Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial

Zeidan, Amer MAmer MZeidanAndo, KiyoshiKiyoshiAndoRauzy, OdileOdileRauzyTurgut, MehmetMehmetTurgutWang, Ming-ChungMing-ChungWangCairoli, RobertoRobertoCairoliHSIN-AN HOUKwong, Yok-LamYok-LamKwongArnan, MontserratMontserratArnanMeers, StefStefMeersPullarkat, VinodVinodPullarkatSantini, ValeriaValeriaSantiniMalek, KamelKamelMalekKiertsman, FlaviaFlaviaKiertsmanNiolat, JulieJulieNiolatRamos, Pedro MarquesPedro MarquesRamosMenssen, Hans DHans DMenssenFenaux, PierrePierreFenauxMiyazaki, YasushiYasushiMiyazakiPlatzbecker, UweUwePlatzbecker2023-12-192023-12-192023-12-0523523026https://pubmed.ncbi.nlm.nih.gov/38065203/https://scholars.lib.ntu.edu.tw/handle/123456789/637991Sabatolimab is an immunotherapy targeting T-cell immunoglobulin domain and mucin domain-3 (TIM-3), an immuno-myeloid regulator expressed on immune cells and leukaemic stem cells. In this trial, we compared the efficacy and safety of sabatolimab plus hypomethylating agent with placebo plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes.enSabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trialjournal article10.1016/S2352-3026(23)00333-2380652032-s2.0-85179098757